SAGE-904 / Supernus Pharma - LARVOL DELTA

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants (clinicaltrials.gov) - P1; N=22; Completed; Sponsor: Sage Therapeutics; Active, not recruiting ➔ Completed; Trial completion date: Apr 2022 ➔ Dec 2021; Trial primary completion date: Apr 2022 ➔ Nov 2021

Clinical • Trial completion • Trial completion date • Trial primary completion date

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants (clinicaltrials.gov) - P1; N=22; Active, not recruiting; Sponsor: Sage Therapeutics; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants (clinicaltrials.gov) - P1; N=22; Recruiting; Sponsor: Sage Therapeutics; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants (clinicaltrials.gov) - P1; N=22; Not yet recruiting; Sponsor: Sage Therapeutics

Clinical • New P1 trial